Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts.
Saved in:
| Title: | Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts. |
|---|---|
| Authors: | Singh N; Division of Infectious Diseases, Department of Medicine, VA Pittsburgh Healthcare System, Pittsburgh, PA, USA. nis5@pitt.edu, Wannstedt C, Keyes L, Mayher D, Tickerhoof L, Akoad M, Wagener MM, Cacciarelli TV |
| Source: | Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society [Liver Transpl] 2008 Feb; Vol. 14 (2), pp. 240-4. |
| Publication Type: | Clinical Trial; Journal Article |
| Journal Info: | Publisher: Wolters Kluwer Health, Inc Country of Publication: United States NLM ID: 100909185 Publication Model: Print Cited Medium: Print ISSN: 1527-6465 (Print) Linking ISSN: 15276465 NLM ISO Abbreviation: Liver Transpl Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
